AEON Biopharma, Inc. (AEON) income statement
AEONNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.12−0.01 (-7.59%)
Close on Nov 20, 2026Market cap $6.14MP/E –Yield –
AEON Biopharma, Inc. financial ratios
See a number that looks wrong?
Close on Nov 20, 2026Market cap $6.14MP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Margins | ||||||
| Effective tax rate | – | 0.00% | – | – | – | – |
| Returns on capital | ||||||
| Return on equity | 93.8% | -46.3% | – | 34.5% | -97.0% | – |
| Return on assets | -901.4% | 841.2% | – | -36.5% | 5.9% | – |
| Return on tangible assets | -901.4% | 841.2% | – | -36.5% | 5.9% | – |
| Return on invested capital | – | – | – | 14.9% | – | – |
| Return on capital employed | 207.4% | -848.1% | – | -47.4% | -1.4% | – |
| Return on total capital | – | – | – | 19.6% | – | – |
| NOPAT | -$10.11M | $72.99M | – | -$38.26M | -$1.53M | – |
| Cash flow quality | ||||||
| OCF / Net income | 0.44 | -0.48 | – | 0.68 | -0.18 | – |
| FCF / OCF | 100.0% | – | – | 100.9% | – | – |
| FCF / Net income | 0.44 | – | – | 0.68 | – | – |
| FCF / EBITDA | 136.0% | – | – | 74.2% | – | – |
| Unlevered free cash flow | -$17.31M | – | – | -$35.89M | – | – |
| Levered free cash flow | -$17.31M | – | – | -$35.89M | – | – |
| Efficiency | ||||||
| CapEx to OCF | -0.02% | – | – | -0.86% | – | – |
| CapEx to depreciation | 0.05 | – | – | 4.50 | – | – |
| Liquidity | ||||||
| Current ratio | 0.49 | 0.11 | 0.48 | 0.12 | 1.00 | 1.36 |
| Quick ratio | 0.49 | 0.11 | 0.48 | 0.12 | 1.00 | 1.36 |
| Cash ratio | 0.44 | 0.00 | 0.40 | 0.12 | 6.14 | 0.00 |
| Working capital | -$3.50M | -$12.56M | -$6.83M | -$72.74M | $639 | $21.41K |
| Net current asset value | -$57.19M | -$30.12M | -$153.67M | -$133.40M | -$17.04M | $21.41K |
| Leverage | ||||||
| Total debt | – | – | – | $23.13M | – | – |
| Net debt | – | – | – | $13.39M | – | – |
| Debt / Equity | – | – | – | -0.08 | – | – |
| Debt ratio | – | – | – | 214.6% | – | – |
| Assets to equity | -0.10 | -0.11 | -0.04 | -0.04 | -16.36 | 3.78 |
| Long-term debt to assets | – | – | – | 214.6% | – | – |
| Long-term debt to equity | – | – | – | -0.08 | – | – |
| Total debt / Capitalization | – | – | – | -8.7% | – | – |
| Long-term debt / Capitalization | – | – | – | -8.7% | – | – |
| Net debt / EBITDA | – | – | – | -0.28 | – | – |
| Total debt / EBITDA | – | – | – | -0.48 | – | – |
| Cash flow to debt | – | – | – | -153.8% | – | – |
| Per share | ||||||
| EPS (basic) | -3.95 | 77.74 | – | -27.36 | – | – |
| EPS (diluted) | -3.95 | 72.93 | – | -27.36 | – | – |
| Book value per share | -4.55 | -51.43 | -21,339.10 | -149.11 | – | – |
| Tangible book value per share | -4.55 | -51.43 | -21,339.10 | -149.11 | – | – |
| Cash per share | 0.25 | 0.02 | 719.19 | 5.05 | – | – |
| Operating cash flow per share | -1.43 | -36.53 | – | -18.46 | – | – |
| Free cash flow per share | -1.43 | – | – | -18.61 | – | – |
| CapEx per share | 0.0003 | – | – | 0.16 | – | – |
| Valuation at period end | ||||||
| Market cap | $12.81M | $21.38M | $267.53M | – | – | – |
| Enterprise value | $6.88M | $20.84M | $251.35M | – | – | – |
| P/E | – | 0.5x | – | – | – | – |
| P/B | -0.2x | -0.7x | -1.7x | – | – | – |
| P/TBV | -0.2x | -0.7x | -1.7x | – | – | – |
| P/OCF | -0.7x | -1.1x | – | – | – | – |
| EV/EBITDA | – | 0.3x | – | – | – | – |
| EV/EBIT | – | 0.3x | – | – | – | – |
| EV/OCF | -0.4x | -1.0x | – | – | – | – |
| Earnings yield | -306.2% | 196.5% | – | – | – | – |
| FCF yield | -135.2% | – | – | – | – | – |
| Per employee | ||||||
| Total employees | 8 | 5 | 10 | 10 | 10 | 10 |
| Operating profit per employee | -$1.60M | $14.60M | – | -$4.84M | -$193.59K | – |
| Net income per employee | -$4.90M | $8.40M | – | -$5.26M | $820.08K | – |
| Free cash flow per employee | -$2.16M | – | – | -$3.59M | – | – |
| Growth | ||||||
| EBIT 1Y growth | -117.5% | – | – | -2,401.6% | – | – |
| EBITDA 1Y growth | -117.4% | – | – | – | – | – |
| Net income 1Y growth | -193.4% | – | – | -740.9% | – | – |
| Net income 3Y CAGR | – | 72.4% | – | – | – | – |
| Diluted EPS 1Y growth | -105.4% | – | – | – | – | – |
| Operating cash flow 1Y growth | 14.7% | – | – | -2,280.5% | – | – |
| CapEx 3Y CAGR | -76.4% | – | – | – | – | – |
| Total assets 1Y growth | 77.0% | -54.1% | -36.5% | -96.1% | 341,813.0% | – |
| Total assets 3Y CAGR | -19.8% | -77.5% | 338.8% | – | – | – |
| Total assets 5Y CAGR | 133.0% | – | – | – | – | – |
| Total equity 1Y growth | -92.6% | 81.3% | 46.8% | -1,598.2% | -79,167.1% | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.